liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers
USI, Switzerland.
USI, Switzerland.
USI, Switzerland.
USI, Switzerland.
Show others and affiliations
2024 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 109, no 11, p. 3602-3614Article in journal (Refereed) Published
Abstract [en]

Hematologic cancers are among the most common cancers in adults and children. Despite significant improvements in therapies, many patients still succumb to the disease. Therefore, novel therapies are needed. The Wiskott-Aldrich syndrome protein (WASp) family regulates actin assembly in conjunction with the Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively in hematopoietic cells and exists in two allosteric conformations: autoinhibited or activated. Here, we describe the development of EG-011, a first-in-class small molecule activator of the autoinhibited form of WASp. EG-011 possesses in vitro and in vivo antitumor activity as a single agent in lymphoma, leukemia, and multiple myeloma, including models of secondary resistance to PI3K, BTK, and proteasome inhibitors. The in vitro activity was confirmed in a lymphoma xenograft. Actin polymerization and WASp binding were demonstrated using multiple techniques. Transcriptome analysis highlighted homology with drugs inducing actin polymerization.

Place, publisher, year, edition, pages
FERRATA STORTI FOUNDATION , 2024. Vol. 109, no 11, p. 3602-3614
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-210476DOI: 10.3324/haematol.2022.282672ISI: 001371211100019PubMedID: 38899342Scopus ID: 2-s2.0-85205083209OAI: oai:DiVA.org:liu-210476DiVA, id: diva2:1921961
Note

Funding Agencies|Swiss National Science Foundation [31003A_163232/1, E!2829 HEMATO-WASP]; FORMAS, Sweden [310030_185185]; European Union [N. 2016-02004]; IKERBASQUE [825489]; Basque Foundation for Science; Basque Government [IT-971-16]; LiU MS Core facility

Available from: 2024-12-17 Created: 2024-12-17 Last updated: 2025-05-05

Open Access in DiVA

fulltext(3609 kB)100 downloads
File information
File name FULLTEXT01.pdfFile size 3609 kBChecksum SHA-512
e9466721a5622bb2f49d42614e68536dbcfdcaf58e2a5712af63b0b85e27f3f1cfb7d366496ed295ff18e203fb74109322d3f60b5dd8678f79db30e1915a5ca8
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Carrasco Del Amor, Ana MariaCristobal, Susana
By organisation
The Division of Cell and NeurobiologyFaculty of Medicine and Health Sciences
In the same journal
Haematologica
Hematology

Search outside of DiVA

GoogleGoogle Scholar
Total: 102 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 88 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf